Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Professor Ming-Shiang Wu, director of the Taiwan Clinical Trial Consortium, elaborates on the activities of the organization and its role to promote Taiwan’s clinical trial infrastructure and attract more international…
Chuan Lin, chairman of TTY Biopharm, one of Taiwan’s leading domestic biomedical players, highlights his ambition to lead the local success story onto the global stage. Chuan goes on to…
Grace Yeh, president and founder of PharmaEngine, gives an update on the company’s recent growth and development of their second nanomedicine cancer treatment. Yeh goes on to explain the unique…
Researchers from Taiwan and the USA may have found a vaccine for the Middle East respiratory syndrome coronavirus (MERS-CoV) – a deadly emerging disease with a mortality rate of over…
Deputy Minister for Science and Technology on Taiwan Fong Chin Su gives his insights on innovation, cybersecurity, and the current state of one of the world’s most exciting biotech industries.…
Gou Jen Wang, the co-founder of Vida BioTechnology, and Bing Chen Gu, General Manager elaborate on how Vida BioTechnology provides added value to its customers by focusing on simplified use,…
Weichyun Wong, president of SCI Pharmtech, discusses the API manufacturer’s transition from a Swiss-owned affiliate to a Taiwanese company. He also talks technology and regulatory challenges, as well as what…
Eugene Huang, chairman, and Hua-Lin Wu, consultant of Blue Blood Biotech Corp., provide insightful information on BB-101, a protein proven to be efficient for wound healing, while sharing their vision…
Michael H.J. Lai, Founder of Body Organ Biomedical Corporation, discusses Ologen’s success as the first ever eye tissue repair product and highlights the importance of global exposure for Taiwan-based companies.…
Ken-Shwo Dai, president and CEO of Visgeneer, explains his biotech’s expertise in medtech, skincare, gene therapy and diagnostics, as well as his plans to take the company public. Can you…
Jassy Wang, CEO of MegaPro Biomedical, a nanomedicine development company specializing in developing nanoparticles and nanomicelles, discusses the evolving nanomedicine market in Taiwan and reveals the company’s plans for future…
Daniel Huang, CEO of Genomics Bioscience, Taiwan’s largest commercial genome sequencing company, and Chairman of Pharmigene, a global leader in the development and manufacturing of genetic tests, documents how he…
See our Cookie Privacy Policy Here